Overview

Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765

Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of VX-765 in subjects with chronic plaque psoriasis treated for 28 days.
Phase:
Phase 2
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated